{
    "ticker": "XTLB",
    "name": "XTL Biopharmaceuticals Ltd.",
    "description": "XTL Biopharmaceuticals Ltd. is a biopharmaceutical company focused on the development of innovative therapies for a range of diseases, particularly autoimmune and infectious diseases. Established in 2003 and headquartered in Rehovot, Israel, XTL is dedicated to advancing the understanding and treatment of immunological disorders. The company's lead product candidate, XTL-002, is aimed at treating patients with systemic lupus erythematosus (SLE), a complex autoimmune disease that affects multiple organs and can lead to significant morbidity. XTL's proprietary technology platform leverages its expertise in protein biochemistry to develop novel therapies with the potential to address unmet medical needs in the fields of immunology and infectious diseases. The company is committed to rigorous scientific research and clinical development, collaborating with leading research institutions to validate its therapeutic approaches. XTL Biopharmaceuticals is also exploring additional indications for its product candidates and aims to expand its pipeline to include treatments for other chronic conditions. With a strong focus on innovation and patient care, XTL strives to bring transformative therapies to the market that can significantly improve the quality of life for patients suffering from debilitating diseases.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Rehovot, Israel",
    "founded": "2003",
    "website": "http://www.xtlbio.com",
    "ceo": "Dr. Rami Elnekave",
    "social_media": {
        "twitter": "https://twitter.com/XTLBiopharma",
        "linkedin": "https://www.linkedin.com/company/xtl-biopharmaceuticals/"
    },
    "investor_relations": "http://www.xtlbio.com/investor-relations",
    "key_executives": [
        {
            "name": "Dr. Rami Elnekave",
            "position": "CEO"
        },
        {
            "name": "Dr. Yossi Eshhar",
            "position": "Chairman"
        }
    ],
    "product_categories": [
        {
            "category": "Therapeutics",
            "products": [
                "XTL-002"
            ]
        }
    ],
    "seo": {
        "meta_title": "XTL Biopharmaceuticals Ltd. | Innovative Biopharmaceutical Solutions",
        "meta_description": "Learn about XTL Biopharmaceuticals Ltd., a leader in the development of innovative therapies for autoimmune and infectious diseases. Explore our pipeline and commitment to patient care.",
        "keywords": [
            "XTL Biopharmaceuticals",
            "Biotechnology",
            "Pharmaceuticals",
            "Autoimmune Diseases",
            "SLE Treatment"
        ]
    },
    "faq": [
        {
            "question": "What is XTL Biopharmaceuticals known for?",
            "answer": "XTL Biopharmaceuticals is known for developing innovative therapies for autoimmune and infectious diseases, particularly its lead product candidate for systemic lupus erythematosus."
        },
        {
            "question": "Who is the CEO of XTL Biopharmaceuticals?",
            "answer": "Dr. Rami Elnekave is the CEO of XTL Biopharmaceuticals Ltd."
        },
        {
            "question": "Where is XTL Biopharmaceuticals headquartered?",
            "answer": "XTL Biopharmaceuticals is headquartered in Rehovot, Israel."
        },
        {
            "question": "What is XTL's main product?",
            "answer": "XTL's main product candidate is XTL-002, aimed at treating systemic lupus erythematosus."
        },
        {
            "question": "When was XTL Biopharmaceuticals founded?",
            "answer": "XTL Biopharmaceuticals was founded in 2003."
        }
    ],
    "competitors": [
        "AMGN",
        "VRTX",
        "ABBV"
    ],
    "related_stocks": [
        "JNJ",
        "PFE",
        "MRK",
        "GILD"
    ]
}